The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | SUCCESSOR-2: mezigdomide, carfilzomib, and dexamethasone in R/R multiple myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the Phase III SUCCESSOR-2 trial (NCT05552976) evaluating mezigdomide, carfilzomib, and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. He highlights a median progression-free survival (PFS) of 18 months and a predictable safety profile. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In this particular trial, we’re able to show that the combination of an oral CELMoD, mezigdomide, with carfilzomib, given weekly IV, and dexamethasone, was associated with a respectable median PFS of 18 months, in a relatively heavily pre-treated patient population with a median of two prior lines of therapy and with about 25% of our patients having received four or more therapies...
In this particular trial, we’re able to show that the combination of an oral CELMoD, mezigdomide, with carfilzomib, given weekly IV, and dexamethasone, was associated with a respectable median PFS of 18 months, in a relatively heavily pre-treated patient population with a median of two prior lines of therapy and with about 25% of our patients having received four or more therapies. Particularly, these patients reflect real-world patients because they had to be pre-treated and resistant to lenalidomide and pre-treated with anti-CD38. So I believe that we have a combination that could be applicable across different clinical settings with a predictable toxicity. We know that mezigdomide is associated with neutropenia. Neutropenia is short-lived. It can ameliorate with holding the drug or by administering G-CSF. We did not have unusual opportunistic infections and I believe that this combination could be given in different patient population and also in between anti-BCMA therapies because there is also evidence that mezigdomide may restore T-cell exhaustion.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
